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ABSTRACT
Current orthopedic implants comprised of plastic, ceramic, or metal alloys are
susceptible to surface degradation at the implant-implant interface. The resulting
microscopic fragments cause tissue irritation that can lead to osteolysis. In addition,
existing percutaneous implants, such as pins used to stabilize fractures, are prone to
bacterial infections due to the inability of the surrounding soft tissue to adhere to the
implant and form a biologic seal. The goal of this Honors Thesis was to develop porous
polymeric implants for orthopedic research and development applications that improve
upon current designs in an attempt to remedy the issues detailed above. A novel approach
was taken to produce the implants, using an Objet30® Desktop 3D printer to create
porous structures comprised of open rhombic dodecahedra. The hypothesis of this study
was that a porous polymeric material will behave much like trabecular bone and allow for
bone, soft tissue, nerve, and vascular in-growth. Thus, degradation of subcutaneous
(osseointegrated) implants and infection associated with percutaneous implants would be
minimized due to increased compatibility with the respective implant site. In addition, the
use of 3D technology will allow for rapid design and production, thus resulting in a
quicker and more economical research and development process. A cell culture
experiment was performed by seeding implants with Buffalo Rat Liver cells. The results
of this experiment showed that the polymeric material used was cytotoxic, with almost no
cell attachment. To test the effectiveness of the porous implants in vivo, both
subcutaneous and percutaneous implants were placed on the dorsa of six New Zealand
White rabbits. The results of this project demonstrated the ability to achieve tissue in-

growth and vascularization of both subcutaneous and percutaneous implants with a
dodecahedral pore size of greater than or equal to 800 microns.
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INTRODUCTION
Healthcare Industry
In recent years the need for improved and more affordable healthcare has been at
the forefront of both government policy agenda and scientific research and development.
As the Baby Boomer generation gets older, a greater percentage of the U.S. population is
becoming dependent upon healthcare services. With such people reaching an age where
they are covered under government healthcare programs, a strain is being placed on state
and federal budgets. Healthcare costs themselves are increasing as well due to high-tech
procedures and rising insurance premiums; approximately $2.7 trillion was spent on
healthcare in the U.S. in 2011 and this figure is expected to increase to $3.6 trillion in
2016.1 An aging population, combined with widespread health issues such as obesity,
brings about a need for improved healthcare. This need has resulted in substantial
research and development in the field of medicine, with these endeavors costing over $90
billion each year.2

The orthopedic industry, which is of primary concern to this thesis, is an
important sector of the healthcare industry that demonstrates an annual growth of 5-7%
on a global scale.3 The American Academy of Orthopedic Surgeons reports that each year
approximately 28.6 million Americans incur some manner of musculoskeletal injury.4 In
order to repair these injuries medical device and equipment manufacturers have
developed products ranging from artificial joints and fixations for stabilizing fractures to
products that replace or stimulate the growth of bone. In the year 2012 it is expected that
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the U.S. market for orthopedic products will reach $14.2 billion.4 Products that are
common for elderly patients who suffer from osteoarthritis are artificial hips and knees.
In 2009, the sale of artificial hips and knees reached $6.7 billion in the U.S., with these
artificial joints selling for $3,000 to $15,000 a piece. 5 In addition to the treatment of
musculoskeletal degeneration, trauma treatment is a critical aspect of orthopedic
medicine, with the global market for trauma devices expected to reach $4.8 billion in
2012.6 Trauma devices can be divided into two categories, internal fixation devices such
as plates and screws, and external fixation devices such as pins and frames. External
fixation, which is an important methodology that is addressed in this thesis, is expected to
result in device sales of $203 million in 2012.6

Traditional Implant Design and Fabrication
The history of orthopedic implants dates to the 1880s when metal plates and
screws were first used for internal fixation. 7 In the 1950s, a Russian by the name of
Gavril Abramovich Ilizarov pioneered the use of external fixation as a means of repairing
fractures. Ilizarov’s design for an external fixation apparatus is still in use today. 7 The
1960s brought about the first total joint replacement when Sir John Charnley of England
discovered that the surfaces of the hip joint could be substituted with metal or high
density polyethylene which were cemented in place.7 Using similar materials and
methods as the first total hip replacement, David L. MacIntosh developed the total knee
replacement in the 1970s.7
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Since the conception of these initial implants alterations and improvements have
been made to the materials of construction (MOC), with joint surface (implant-implant
interface) integrity being of utmost importance to internal implants. Current internal
implants are comprised of materials such as titanium, cobalt-chromium-alloy, and highdensity polyethylene. In most instances metal implants are highly polished in order to
prevent wear on the surrounding bone and to avoid breakdown of the implant itself.
Polyethylene is used as an MOC as its smooth surface is also thought to prevent these
issues. Although degradation of implant stems and screws are of concern, the breakdown
of the bearing surfaces of artificial joints is the major issue with internal orthopedic
implants. In the United States alone, there are over 1 million hip and knee replacements
performed each year.8 These replacements typically have a success rate of ~90% over a
ten year period, with aseptic loosening being the major complication and reason for
revision.9 Aseptic loosening, which is the loosening of implant components in the
absence of infection, is believed to be caused primarily by small fragments of implant
material known as wear particles. It has been recently discovered that the majority of
wear particles, which result from implants made from metals, ceramics, and
polyethylene, are submicroscopic and can be as small 10nm or less in length. 9 The small
size of these wear particles allows them to easily spread to different areas of the joint,
such as the bone-implant interface, where they can then cause inflammation and
osteolysis.

Percutaneous implants used in external fixation are comprised of similar MOC as
internal implants, with most pins made out of stainless steel or titanium. Pins traditionally
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have smooth surfaces and are terminally threaded to allow them to be screwed into the
bone. In order to stabilize the fracture, the exposed portions of the pins are then attached
to an external fixator which consists of metal rods that can be tightened or adjusted.
Compared to the use of internal plates and nails, external fixation causes less soft tissue
trauma and allows for more precise alignment and improved stability. Percutaneous pins
may also be coated with the calcium-phosphate mineral hydroxyapatite (HA).
Hydroxyapatite has been shown to promote bone growth, and in the case of percutaneous
pins it is effective in decreasing infection rates and preventing pins from loosening. 10
Despite advancements in percutaneous implant designs and procedures, infection as a
result of external fixation is still quite common. The percentage of deep infections
observed in patients with external fixation devices is approximately 16.4% overall
(almost 1 out of every 6 patients), with chronic osteomyelitis (bone infection) occurring
in 4.2% of patients.11

A majority of the orthopedic implants that are currently on the market are
manufactured by traditional methods such as machining, molding, or compression. Metal
implants are typically machined or forged, and polyethylene implants are constructed
from polyethylene powder through various consolidation methods (e.g. ram extrusion). 12
Post-fabrication modifications can be made to implants as well, such as nitriding which
produces a hard surface of titanium nitride, and ion implantation which increases the
implants resistance to wear.12 In addition to these common manufacturing processes,
technological advancements have led to fabrication methods that are faster and more
precise. Of particular interest is the method of electron beam melting (EBM) which
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employs an electron beam to melt metallic powders under vacuum to produce three
dimensional (3D) structures. EBM can produce solid structures that have the mechanical
properties required for orthopedic implants. The Swedish company Arcam™ developed
the technology of EBM and the concept of selective laser melting. Arcam™ EBM
machines allow users to develop implant designs using computer-aided design (CAD)
programs and then have the implants constructed in a matter of hours.13 There are
currently several medical device manufacturers using Arcam™ EBM technology to
produce orthopedic implants that are European Conformity (CE)-certified and Food and
Drug Administration (FDA) approved, including spinal implants, hip implants, and
acetabular cups.13

The current methods of orthopedic research and development (R&D) are often
costly and time intensive. Material costs can range from $6-$7/lb for cast titanium to
$41/lb for forged cobalt chrome (1992 world commodity prices). 14 Developing a new
implant involves designing and testing several iterations, and using materials such as
titanium or cobalt chrome for prototype development can dramatically increase overall
development costs. Another major contributor to the cost of designing an implant is the
manufacturing process, with a forged cobalt-chrome primary hip costing between $80
and $125/piece to manufacture and a cast titanium component costing between $100 and
$150/piece to manufacture.14 Due to its curved shape, the manufacturing of a tibial
condyle to be used in knee replacements can take upwards of 30 hours. Similarly, the
time it takes to machine and finish a total hip implant can be in excess of 20 hours. 14
Given the considerable amount of time between implant design and production, implant
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R&D can be a lengthy process. In total, the R&D costs of a new orthopedic implant can
be on the order of $50 million.15 The manufacturing of implants through the use of EBM
technology mentioned above helps to reduce R&D (and product) costs. Arcam™’s
estimated manufacturing cost is $144/ machine hour, which includes operator and
material costs and additional expenses. 16 Using an Arcam™ EBM machine, a hip implant
can be manufactured for approximately $260 in a fraction of the time it takes to produce
the same implant by traditional methods. 16 In terms of economics, the downside of EBM
machines is their considerable upfront cost which in many cases render them
impractical/uneconomical as a means of manufacturing (or for use in research
applications). EBM machines sold by Arcam™ cost $500,000 or more.17
Porous Implants
The use of porous materials/structures for internal orthopedic implants is quite
common. Porous implants were initially developed in order to achieve osseointegration
and attachment of the implant without the use of cement, which was thought to a source
of wear particles. Porous implants are able to achieve osseointegration and soft tissue ingrowth; however, issues with wear particles are still present. The most common porous
structures that are used are titanium plasma spray coatings and cobalt-chromium-alloy
fiber metal mesh.18 Despite the relatively low porosities of titanium plasma spray
coatings and cobalt-chromium-alloy fiber metal mesh (20-30% and 40-50%, respectively)
these conventional porous materials have been proven capable of facilitating bone ingrowth.18 In addition to porous coatings, fully porous implants exist that seek to imitate
the trabecular structure of cancellous (spongy) bone. Trabecular implants are typically
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made using vapor deposition of tantalum metal. With a porosity of 80.9% and an elastic
modulus closer to that of bone tissue, trabecular implants composed of tantalum metal
demonstrate greater biocompatibility with bone than implants with porous coatings. 18
Implants with manufacturer-defined trabecular structure can also be made using CAD
software and an EBM machine.19

In terms of percutaneous implants, research has been performed investigating
means to prevent infections in external orthopedic fixations. Special surface modification
using diamond-like carbon coatings to prevent bacterial adhesion and bio-film formation
has been performed.20 At this point in time, porous material/design is not used
commercially for percutaneous implant applications. However, the idea of using soft
tissue in-growth facilitated by porous structures to create a biologic seal has been
researched for many years. The studies performed on this subject have had mixed
success. In one study, porous button shaped implants (subcutaneous disk and
percutaneous post) were made by sintering HA powder and polyurethane beads.21 All of
the implants, which were placed through the dorsal skin of adult mongrel dogs, fell out or
had to be removed 1 month post implantation due to severe bacterial infection.21 Another
recent study, which used porous coated (~400μm pore size) titanium implants, was
performed to analyze the potential of developing osseointegrated percutaneous implants
for amputee prosthetics.22 These porous implants (subcutaneous disk and percutaneous
post), which were implanted in New Zealand White rabbits, showed a 7-fold decreased

8
risk of infection compared to similar smooth implants after being inoculated with
Staphylococcus aureus while in vivo.22

Implant Application of 3D Printing
As with any industry, the ability to cheaply and rapidly design and produce
prototypes of new products results in more efficient and economical orthopedic implant
R&D. Quick and economical prototyping can be accomplished through a process known
as rapid prototyping. As the name suggests, rapid prototyping methods are faster than
traditional fabrication techniques and allow for more precision and control with CAD
software used to design the object that is to be made. 3D printing is an additive method of
rapid prototyping that creates 3D objects by layering material in the shape/profile defined
by a 3D computer model. Selective laser sintering (SLS), selective laser melting (SLM),
electron beam melting (EBM), and fused deposition modeling (FDM) are all types of 3D
printing. As mentioned above, FDA approved implants (porous and non-porous) have
been made utilizing 3D printing through the use of Arcam™ EBM machines. SLM 3D
printing gained attention recently when it was used to create a tailor-made titanium
jawbone for an elderly patient suffering from osteomyelitis.23 As for 3D printing of nonmetallic implants, this appears to be an area of very little development. A study was
performed to develop porous ceramic scaffolding for bone tissue engineering applications
using a specialized 3D printer; however, the manufacturing process also involved a
sintering step which in turn caused shrinkage of the scaffold bodies. 24 Despite the field of
3D printed plastic (polymeric) implants being seemingly untouched, last year the 3D
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printer manufacturer Objet ® released a rigid plastic-like biocompatible material approved
for skin or mucosal-membrane contact.25 Although this material is not specifically
designed/ approved for internal implantation, it signifies the potential ability to integrate
3D printing in the production of medical devices (i.e. orthopedic implants). In addition,
the development of biocompatible polymeric materials that can be 3D printed allows for
this technology to be used as an economical means of R&D for in vivo testing of implant
prototypes.
Objective
Given the performance characteristics and production costs of current orthopedic
implants, in addition to the significant need for these implants, it is evident that there is
meaningful work that can be performed in the development of novel materials and
fabrication processes. The objective of this study was to develop a porous polymeric
implant, using 3D printing technology, which facilitates soft tissue in-growth for use in
orthopedic R&D testing of subcutaneous and percutaneous implants. For internal
implantation the porous structure should allow for soft tissue in-growth and
osseointegration, both of which will aid biocompatibility and improve the implant’s
intended function. For percutaneous implantation the pores will allow for soft tissue ingrowth which will form a biologic seal between the implant and dermal layer, thus
preventing bacterial infection. Polymer, as opposed to metal, was chosen as the material
of construction as only low levels of porosity are achievable with porous metallic
materials (with the exception of tantalum). In addition, due to the structural
characteristics of porous metals they can only be used as implant coatings. 18 The elastic
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moduli of cobalt-chromium and titanium alloys are 210 GPa and 110 GPa, respectively;
whereas the elastic modulus of bone ranges from 0.1-18 GPa.18 It is critical that an
implant has a similar elastic modulus to that of bone in order for osseointegration to
occur. Given these structural discrepancies, current porous metallic materials are
deficient in terms of biocompatibility and long term reliability. It is noted that porous
tantalum materials have been developed that improve biocompatibility and mechanical
properties; however, the costs associated with materials and construction are major
disadvantages of implants comprised of tantalum. 3D printing was selected as the method
of fabrication for several reasons. First, rapid prototyping/manufacturing 3D printing
allows for iterations of implant designs to be quickly modeled and manufactured. 3D
printing also allows complete control over implant design, such as overall shape and
component dimensions (i.e. pore size). Lastly, 3D printing offers a more economical
method of performing orthopedic implant R&D, as manufacturing and labor costs as well
as material costs (in this case a polymer) are lower than those of traditional methods.

MATERIALS AND METHODS
Objet® Printer
With the decision made to produce the porous polymer implants through the use
of 3D printing technology, a 3D printer capable of rendering porous structures was
required. The printer selected was an Objet30® Desktop 3D printer located at the
Manufacturing Applications Center (MAC) at the University of Southern Maine,
Gorham, Maine. The Objet30® Desktop works by printing 16-micron-thick layers of a
photopolymer material in both the horizontal and vertical direction until the 3D structure
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is complete. After each layer is printed, UV light is used to cure the material. In order to
support the structure while it is being printed a gel-like support material is laid down
simultaneously, and is later removed by either a physical or chemical process. Structures
as thin as 28-microns can be printed, with an accuracy of 0.1mm (see Appendix A for
complete technical specifications). The retail price of the Objet30® Desktop printer at
MAC at the University of Southern Maine was approximately $48,000.
Implant Material
In order to fully evaluate the feasibility of using 3D printing to generate effective
porous implants, an in vivo small animal trial was performed. As such, the implant
material required the mechanical strength to withstand animal movement, material
properties to withstand both sterilization and in vivo physiological conditions
(temperature, pH, etc.), and be biocompatible in vivo. With the Objet30® Desktop printer
selected for production of the implants, the material options were limited to those that
could be printed by this specific printer. Of the materials capable of being printed, Vero
White Plus Fullcure 835 was selected for its material and mechanical properties as a
polypropylene-like plastic (see Appendix B for complete technical specifications).
Material Testing
To test the effects of temperature on Vero White Plus Fullcure 835, samples of
the material (2.5cm diameter, 5mm thick discs) were placed in a water bath for 30min at
40oC to simulate the internal temperature of a rabbit.26 In addition, samples of Vero
White Plus Fullcure 835 were exposed to the following solutions for 30min: 70% ethanol,
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7.5% hydrogen peroxide. Samples of Vero White Plus Fullcure 835 were also exposed to
0.9% saline in water for a period of one week.
Implant Design
In order to evaluate the performance of 3D printer generated porous polymer
implants in both subcutaneous and percutaneous applications two implant designs were
developed.
For the evaluation of subcutaneous applications a simple rectangular block design
was developed. In order to allow for direct comparison of results with a previous small
animal trial using rectangular blocks of alumina ceramic, the dimensions were set at
30mm long, 20mm wide, and 6mm thick. The blocks also included a 2mm diameter
suture hole in each of the four corners to allow for the blocks to be anchored to the
subcutaneous tissue. Figure 1 presents the basic block design developed using the 3D
modeling program Google SketchUp 8.

Figure 1: Rectangular block design developed using Google SketchUp 8
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With the basic block design in place, attention was turned to development of the
porous structure of which the block would be comprised. As the blocks were to be printed
by an Objet printer, the program employed to design the porous structure was required to
produce a computer-aided design (CAD) file that can read by Objet printers. With
assistance from engineers at the Advanced Manufacturing Center (AMC) at the
University of Maine, Orono, Maine the porous block design (and all other implant
designs) was developed using the SolidWorks 3D CAD software package. In developing
a porous structure, or matrix, using SolidWorks several limitations were encountered.
Given the computational demands of creating 3D objects in SolidWorks, and the complex
nature of a porous structure, the design was limited by the file size that the computer
could process and that the Objet printer could produce. Congruently, a random porous
design that would require the pores be individually drawn by hand was forgone in favor
of a patterned design of identical pores that required less design work and resulted in a
smaller overall file. As such, a patterned design was developed that attempted to imitate
trabecular bone. The patterned design was comprised of rhombic dodecahedrons which
have 12 open rhombic faces, 24 edges (struts), and 14 vertices. Rhombic dodecahedra
were used in order to create a complete space filling matrix. The rhombic dodecahedra
were placed side-by-side in rows and then stacked on top of each other. Figure 2 presents
a matrix of rhombic dodecahedra in two rows. Figure 3 presents a computer simulated
image of the trabecular bone structure of a human vertebra for comparative purposes.27
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Figure 2: 2x2x2 matrix of rhombic dodecahedra drawn in SolidWorks.

Figure 3: Trabecular bone structure in human vertebrae. Courtesy of Berkeley Lab.

With the pore design determined, attention was turned to the pore dimensions.
Similar small animal trials performed at the University of Maine using porous titanium
and alumina ceramic implants determined that tissue attachment may occur over a range
of pore sizes. However, the pore size of trabecular bone is typically defined as 500-600
microns.28 The second pore dimension, strut thickness, is more varied than pore size (see
Figure 3 above). However, the strut thickness for other manufactured porous implants
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seeking to imitate trabecular bone (e.g. Trabecular Metal™ made from tantalum metal) is
of the order of 100-150 microns.18 With the capability to easily change dimensions in
SolidWorks and rapidly print new implant designs, rectangular block implants were
printed with several different pore dimensions. Blocks were printed with both 400 and
800 micron (approx.) internal pore diameters and a strut thickness of 76 microns
(approx.). A third iteration of the block design set the internal pore diameter to 564
microns (approx.), and increased the strut thickness to 152 microns (approx). In addition
solid polymer reinforcements were added to the inside of the suture holes and along the
outer edges of the block. A fourth iteration of the block design set the internal pore
diameter to 1200 microns (approx.), increased the strut thickness to 280 microns
(approx), and employed the same solid polymer reinforcements of the third design. It
should be noted that the 400 micron dodecahedron blocks were mistakenly printed at an
increased thickness, which was most likely due to a dimensional error in the SolidWorks
file. Images of the 400 and 800 micron dodecahedron blocks are presented in Figures 4
and 5, respectively. The 1200 micron dodecahedron block with reinforcements is shown
in Figure 6. Figure 7 presents the SolidWorks design of the 1200 micron dodecahedron
block complete with dimensions (millimeters).
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Figure 4: 400 micron dodecahedron block for subcutaneous implantation.

Figure 5: 800 micron dodecahedron block for subcutaneous implantation.

Figure 6: 1200 micron dodecahedron block for subcutaneous implantation.
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Figure 7: 1200 micron dodecahedron block SolidWorks design.

For the evaluation of percutaneous applications a button design was developed
that was modeled after a tuxedo stud. The button design consisted of a circular base, post,
and domed cap made out solid polymer. The base and post were covered with
approximately 3mm of porous matrix. The concept behind the design was that, once
implanted, the base of the button would sit on top of the subcutaneous tissue, the post
would pass through the dermal layers, and the cap would sit on top of the skin. The
porous matrix covering the base and post would allow for tissue in-growth, while the
solid plastic cap would aid in keeping the implant in position and prevent skin growth
over the implant. The porous matrix employed to cover the base and post uses the same
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design as the porous matrix employed for the blocks. Figure 8 presents the initial button
design that was developed using Google SketchUp 8.

Figure 8: Button design developed using Google SketchUp 8

With the button design set, SolidWorks was utilized to develop three different
porous button designs. The first set of buttons that were printed had a pore size of 400
microns (approx.) and a strut thickness of 76 microns (approx.). The second set of
buttons that were printed had a pore size of 564 microns (approx.) and a strut thickness of
152 microns (approx.). The third set of buttons that were printed had a pore size of 1200
microns (approx.) and a strut thickness of 280 microns (approx.). In order to provide
enhanced rigidity and durability, the porous matrix of both the second and third designs
included a cage of solid polymer along the exposed edges. Figures 9 and 10 present side
views of the first and second button designs created in SolidWorks, respectively. Figure
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11 presents the third button design in SolidWorks, and an image of the printed product is
given in Figure 12. The SolidWorks designs and images of the printed products of the
second and third buttons are presented side-by-side in Figures 13 and 14, respectively.

Figure 9: 400 micron dodecahedron button side view in SolidWorks.

Figure 10: 564 micron dodecahedron button side view in SolidWorks.

20

Figure 11: 1200 micron dodecahedron button design in SolidWorks.

Figure 12: 1200 micron dodecahedron button design for percutaneous implantation.
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Figure 13: 564 micron dodecahedron button (left) vs. 1200 micron dodecahedron button
(right), SolidWorks Design

Figure 14: 564 micron dodecahedron button (left) vs. 1200 micron dodecahedron button
(right) for percutaneous implantation.
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It is evident from examination of Figures 13 and 14 that a difference in the shape
of the base exists between the two implant designs. Since the pores have flat sides and
sharp vertices the base cannot be made to be perfectly circular. As the pore size increased
the design of the base was modified to connect the number of exposed vertices by
employing lines, rather than circular edges. It is noted that all block and button images
were taken after the removal of the support material. The support material was removed
by immersing the implants in a 2% NaOH aqueous solution. The implants were immersed
for a time approximately three days, with the solution changed daily. Figure 15 presents
images of an 800 micron dodecahedron block and a 400 micron dodecahedron button
encased in support material prior to soaking.

Figure 15: 800 micron dodecahedron block and 400 micron dodecahedron button prior to
removal of support material.

Cell Culture
In addition to performing a small animal trial to evaluate in vivo performance of
the implants, cell culture experiment were undertaken in order to assess basic cell
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attachment, and to assess potential cytotoxicity of the implant material (Vero White Plus
Fullcure 835). Buffalo Rat Liver cells (BRL 3A) from ATCC™ were selected due to their
adherent growth properties and relative ease of culturing. After propagating the BRL
cells and culturing them to confluency, the cells were re-suspended and seeded on a
variety of the different porous plastic designs. For comparative purposes, the cells were
also seeded on tantalum foam plugs and a porous alumina ceramic block. To examine
potential cytotoxicity of the support material employed during printing, cells were seeded
on samples of support material. The detailed cell culture protocol is given in Appendix D.
It should be noted that prior to the cell culture experiment took place, a sterilization test
was performed in order to determine the effectiveness of sterilizing the implants by
means of a liquid sterilization process (see Appendix C). The objects seeded in the cell
culture experiment were either sterilized by the liquid process described in Appendix C,
or via ethylene oxide at Eastern Maine Medical Center, Bangor, Maine. The objects that
were seeded in the cell culture experiment, and the means by which they were sterilized,
are detailed in the results section.

Implantation
Given that the objective of the study was to evaluate the performance of porous
polymer implants in facilitating soft tissue in-growth, the most practical and
representative means of assessment was to perform an in vivo small animal trial. Upon
receiving approval from the Institutional Animal Care and Use Committee (IACUC) of
the University of Maine, Orono to perform a small animal trial, six New Zealand White
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strain rabbits (Oryctolagus cuniculus) each weighing 4-4.5 kg were obtained. The rabbits
were given sufficient time to acclimate to the Small Animal Research Facility (SARF) at
the University of Maine, Orono and were subjected to thorough physical examinations by
the institutional veterinarian, Dr. James Weber.
Prior to implantation, a simple allergy test was performed on the rabbits in order
to determine whether general skin contact with the implant material would illicit an
immune response. The allergy test involved taping plastic discs (2.5cm diameter and
5mm thick) to the inside portion of the rabbit’s ear with medical grade tape. The discs
remained in place for several days before the ear was examined for signs of irritation.
To allow for sufficient spacing of implants, and to minimize animal manipulation,
the subcutaneous and percutaneous implants were placed along the dorsum of the rabbits,
on either side of the spine. Given the high risk of infection associated with percutaneous
implants, the rabbits received either all subcutaneous implants, or all percutaneous
implants; so as not to risk losing successful implants as a result of unsuccessful implants
of a different design. Surgical procedures were performed by Dr. Ian Dickey, an IACUC
approved, licensed orthopedic surgeon in the surgery suite of the SARF. Operations were
performed under general anesthesia, with each rabbit receiving four implants. The
implants were anchored to the subcutaneous tissue with absorbable sutures, and the
incisions were closed with subcuticular sutures. Each rabbit was given both non-steroidal
anti-inflammatory agents as well as anesthetics for pain management. The rabbits were
closely observed post-operation to ensure their comfort and return to normal activity
patterns and feeding behavior. Section 7c. of Appendix E (IACUC Protocol Review
Form) provides a complete description of the surgical procedures. In order to allow
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sufficient time for soft tissue in-growth it was decided that six weeks would be given
between the time of implantation and removal of implants, with any signs of infection or
animal distress warranting early removal of implants and/or removal from the study and
euthanization.

Histology
For the removal of the subcutaneous implants a single incision through the skin
was made down the dorsal midline and the four implants (two on either side of spine)
were harvested en bloc with their surrounding soft tissue. For the removal of the
percutaneous implants four incisions through the skin were made around each implant,
thus harvesting the implants in square sections of dermal tissue. After performing a gross
anatomical analysis, the implants were placed in containers of formalin for preservation
until histologic examination was performed.
Histologic examination commenced with cutting of the harvested implants into
cross-sections to reveal the interior of the implants, and thereby enable evaluation of the
degree of tissue in-growth. Subsequently, the tissue plus implant cross-sections were
processed and embedded in paraffin. The paraffin blocks were sectioned into ribbons
using a Leica RM2155 Microtome. The resulting ribbons of tissue plus implant were
mounted on glass slides and stained with hematoxylin and eosin (H&E) which stains
nuclei blue and stains other cellular structures shades of pink or red. The slides were
subsequently examined under a microscope for determination of cell formation and
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neovascularization, and to assess if inflammation or cell death had occurred. Appendices
F-H detail the procedural aspects of the histological processes.

RESULTS AND DISCUSSION
Material Testing
Equilibrating the Vero White Plus Fullcure 835 samples at 40oC in water resulted
in a slight increase in pliancy. However, this effect was not permanent and the samples
regained their normal levels of rigidity soon after removal from the water bath.
Exposing Vero White Plus Fullcure 835 samples to 7.5% hydrogen peroxide, and
seperably 70% ethanol, was undertaken to determine if these chemicals could be used as
sterilants (see Appendix C) without degrading the implants. Neither of these treatments
resulted in obvious degradation of the plastic, or altering of its mechanical properties.
Equilibrating Vero White Plus Fullcure 835 samples with 0.9% saline solution
was performed to evaluate the materials ability to withstand in vivo ionic conditions; no
signs of degradation of the polymer, or altering of its mechanical properties were
observed.

Implant Design
As detailed in the Materials and Methods Section, a series of design iterations
were developed for both the subcutaneous and percutaneous implants. The iterations
occurred due to the desire to as closely possible mimic the structure of human trabecular
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bone. Pre-operative analysis of all implant designs was performed by the project team in
order to gauge potential for success and to avoid heedless use of animal subjects. The
pre-operative analysis involved visual evaluation of the pore size and structure, the
overall implant design, and determination of the extent of scaffolding material removal.
The pre-operative analysis led to several design iterations prior to implantation.
As stated in the Implant Design portion of the Materials and Methods Section,
typical pore dimensions for human trabecular bone are known. These dimensions were
used as a guide for the design of the first generation of porous implants. However, visual
inspection of the printed implants revealed a discrepancy between the pore size of
trabecular bone and the pore size of the printed implants, with the pore size of the printed
implants being considerably smaller. The primary reason for the discrepancy is believed
to be a miscommunication during the design process, specifically, the internal diameter of
the rhombic dodecahedra were set to mimic the internal pore diameter of trabecular bone.
Comparison of Figures 2 and 3 reveals that many of the pore openings of human
trabecular bone are close in size to its internal pore diameter, whereas with the rhombic
dodecahedron design the pore openings (rhombic faces) are significantly smaller than its
internal pore diameter. Since the pore openings serve as passages for tissue in-growth it is
presumably critical that the size of the pore opening size be physiologically accurate. In
addition, it is noted that the actual dimensions printed may not accurately reflect the
design dimensions. With the dimensional issues encountered, appropriate changes were
made to the implant design, resulting in several iterations of blocks and buttons with
increasing internal pore diameter. Although the material testing did not show material
degradation for any condition, pre-operative inspection of liquid sterilized 400 micron
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and 800 micron implants (block and button design) showed breakdown of the porous
matrix and softening of the overall structure. These observations were believed to be a
result of the minimal strut thickness employed and rocking during sterilization, rather
than chemical degradation of the material. As such, with the pore size increase to 564
microns the strut thickness was also increased and a protective cage was added. A
wicking test with methylene blue was performed on a 564 micron button to test porosity.
This test showed very little wicking of the methylene blue into the button. As the
methylene blue test indicated inadequate porosity with 564 micron pores, blocks and
buttons were designed with 1200 micron pores, increased strut thickness, and a protective
cage (see Figures 7 and 11). Appendix I contains a complete set of design drawings
(Figures 29-36) for the 1200 micron pore and 1200 micron button.
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Cell Culture
The layout of the cell culture experiment is provided in Table 1.

Table 1: Cell Culture Experiment
Well
Petri
Dish
Plate
1

2 partial 400 micron dodecahedron buttons + 2 partial 800 micron dodecahedron buttons
1
2
3
4
5
6
7
8
empty

empty

empty

1200 μm
button base
crosssection
564 μm
block
crosssection

1200 μm
button
base crosssection
564 μm
block
crosssection

control

control

1200 μm
block
1200 μm
block
crosssection

disc

disc

disc

disc

disc

disc

disc

disc

564 μm
block
quartered

solid
block

solid
block

400
μm
block

400
μm
block

control

400 μm
block

control

control

control

empty

empty

empty

Plate
2

control

Plate
3

control

Plate
4

800 μm
block

Plate
5

alumina
ceramic
block

empty

empty

empty

two
tantalum
foam
plugs

Plate
6

scaffold
sample

control

control

control

scaffold
sample

control

control

control

Plate
7

1200 μm
block

empty

empty

disc

empty

empty

empty

disc

Plate
8

1200 μm
button
base

empty

empty

564 μm
button base

empty

empty

empty

empty

Plate
9

control

control

control

control

control

control

control

control

The experiment consisted of two trials; the Petri dish and plates 1-3 in Trial #1,
and plates 4-9 in Trial #2.
For Trial #1 all objects were sterilized using the process described in Appendix C.
After 24hr incubation with BRL cells, the results of Trial #1 were as follows. The
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implants in the Petri dish had 0% attachment, and complete cell death. In plates 1-3 of
Trial #1, a majority of the wells demonstrated 0% attachment (to the object or well itself)
and complete cell death. Several of the solid objects (wells 5-8 of plates 1+2 and wells
5+6 of plate 3) demonstrated low levels of attachment (20-30%), while the control well in
plate 3 had ~75% attachment.
For Trial #2 all objects were sterilized using the process described in Appendix C
except for the block in well #1 of plate 7, the buttons in plate 5, and the objects in plate 2;
these objects were ethylene oxide sterilized according to standard hospital procedures.
The alumina ceramic block and small tantalum foam plugs of plate 2 demonstrated no
signs of cytotoxicity and possessed confluent cell growth. The scaffold material samples
had no cell adhesion, but did not demonstrate cytotoxicity. All other objects cultured in
Trial #2 demonstrated levels of cytotoxicity and little to no cell attachment.
Given the results of the cell culture trials, several conclusions can be made. The
levels of cell growth and attachment on the control wells, and on the alumina ceramic
block and tantalum foam plugs lead to the conclusion that the BRL cells were
successfully cultured. This conclusion, combined with the cytotoxicity and low levels of
attachment observed with the 3D printed implants, suggests that the 3D printed implants
were cytotoxic. Culturing on the scaffold material samples did not indicate that the
scaffold material were cytotoxic (however, no visible cell attachment occurred).
Therefore, it is concluded that the polymer material of the implants is thereby cytotoxic.
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Implantation
The first of two sets of surgical implantations occurred on March 19, 2012 and
consisted of subcutaneous implantation in two rabbits (designated as Rabbit #1 and
Rabbit #2). The two rabbits each received two 800 micron dodecahedron blocks, with the
blocks placed cranially on either side of the spine. In addition, the two rabbits received
two 400 micron dodecahedron blocks, with the blocks placed caudally on either side of
the spine.
The second set of surgical implantations occurred on April 20, 2012 and consisted
of subcutaneous implantation in one rabbit (designated as Rabbit #3) and percutaneous
implantation in a separate rabbit (designated as Rabbit #4). Rabbit #3 received four 1200
micron dodecahedron blocks, two placed cranially on either side of the spine and two
placed caudally on either side of the spine. Rabbit #4 received four 1200 micron
dodecahedron buttons, two placed cranially on either side of the spine and two placed
caudally on either side of the spine (individual incisions made for each implant). The
procedures for both the subcutaneous and percutaneous implantations are provided in
Section 7c. of Appendix E (IACUC Protocol Review Form).
The results of the cell culture experiment indicating that the polymer employed to
construct the implants was toxic to BRL cells were obtained in the second week of April
2012. As such, it was decided that the implants in Rabbit #1 would be harvested ahead of
schedule to determine if the cell culture results translated to in vivo results. It is noted
that during the weeks following implantation, Rabbit #1 demonstrated normal levels of
activity and typical feeding behavior, with no signs of distress evident. Rabbit #1 was
sacrificed April 20, 2012 (see section 7a. of Appendix E (IACUC Protocol Review Form)
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for the euthanization procedure). The implants were harvested as described in the
Materials and Methods Section. During removal of the implants, a gross anatomical
analysis of the rabbit did not reveal any abnormalities. A complete necropsy of the rabbit
post implant removal indicated that the animal was in good health. Neither of the 400
micron dodecahedron blocks removed from Rabbit #1 demonstrated substantial
attachment of the surrounding tissue. Instead, the formation of interstitial pockets
surrounding the implants was observed (see Figure 16). This result may be due to either
the small pore size of the blocks or the cytotoxic nature of the implant material.
Conversely, both the 800 micron dodecahedron blocks removed from Rabbit #1
demonstrated considerable tissue attachment as well as what appeared to be complete soft
tissue in-growth, including blood vessel formation along the implants (see Figure 17).

Figure 16: Removal of a 400 micron dodecahedron block from Rabbit #1.
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Figure 17: Removal of an 800 micron dodecahedron block from Rabbit #1.

Upon review of the partially successful in-growth results of Rabbit #1, the
decision was made that Rabbit #2 would be given the full six week trial period before
implant removal. Rabbit #2 was sacrificed May 11, 2012, and the implants were
harvested as described in the Materials and Methods Section. The results of implant
removal from Rabbit #2 were essentially the same as those of Rabbit #1, with the 400
micron dodecahedron blocks resulting in pocket formation rather than tissue attachment
(see Figure 18), and the 800 micron dodecahedron blocks demonstrating excellent soft
tissue in-growth (see Figure 19).
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Figure 18: Removal of a 400 micron dodecahedron block from Rabbit #2.

Figure 19: Removal of an 800 micron dodecahedron block from Rabbit #2.

In addition to removing the implants from Rabbit #2, Rabbit #3 was also
sacrificed May 11, 2012. The decision derived from the apparent success of soft tissue ingrowth in the larger pore size in rabbits #1 and #2, suggesting that substantial tissue ingrowth into the 1200 micron dodecahedron blocks of Rabbit #3 may have been achieved
in a shorter amount of time. In addition, with knowledge that the implant material was
cytotoxic, it was decided that it was best to remove the implants as soon as possible.
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Indeed, the 1200 micron dodecahedron blocks demonstrated a very high level of both
tissue attachment and soft tissue in-growth (Figures 20 and 21). The cranially placed
implants showed a small amount irritation of the subcutaneous tissue in the region of
placement, a fact attributed to the anatomical locations of these implants and tissue
movement arising from rabbit movement.

Figure 20: Removal of a 1200 micron dodecahedron block from Rabbit #3

Figure 21: 1200 micron dodecahedron block removed from Rabbit #3
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Rabbit #4, with the percutaneous implants, was closely monitored post-operation
due to the increased inherent increased potential for infection. However, after receiving
NSAIDs and anesthetics for only two days post-operation, and antibiotics for only three
days post-operation, considerable healing was evident around the post of the implants.
Indeed, the skin layer was well-apposed to the post and no signs of infection were evident
(see Figure 22).

Figure 22: Percutaneous implant wound closure 24 hours post implantation.

Rabbit #4 was sacrificed on May 11, 2012 (for the same reasons as Rabbit #3),
and the percutaneous implants harvested en bloc as described in the Materials and
Methods Section. It is noted the caps of three of the four buttons implanted into Rabbit #4
had been broken off through action of the rabbit, with the caps broken off on May 5, 6,
and 10. Thus it was decided that the implants should be removed before skin grew over
the top of the exposed posts (Figure 23). Upon removal, it was evident that soft tissue ingrowth had occurred not only at the base of the button but also through the posts that
were still attached and the posts that were snapped off (Figures 24 and 25). As with
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Rabbit #3, a slight amount of subcutaneous irritation was noticed at the cranially located
implant site. Table 2 provides implantation and removal information for the four rabbits.

Figure 23: External view of the percutaneous implants of Rabbit #4.

Figure 24: Soft tissue in-growth into the base of a button from Rabbit #4.
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Figure 25: Soft tissue in-growth into the post of a button from Rabbit #4.

Table 2: Rabbit Implantation Information
Rabbit

Implant Information

1

400 and 800 micron dodecahedral blocks (two each)
implanted subcutaneously 3/19/2012. Implants removed
4/20/2012. 32 day implantation.

2

400 and 800 micron dodecahedral blocks (two each)
implanted subcutaneously 3/19/2012. Implants removed
5/11/2012. 53 day implantation.

3

1200 micron dodecahedral blocks (four) implanted
subcutaneously 4/20/2012. Implants removed 5/11/2012.
21 day implantation.

4

1200 micron dodecahedral buttons (four) implanted
subcutaneously 4/20/2012. Implants removed 5/11/2012.
21 day implantation.
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Histology
At the time of the submittal of this thesis, only the histological results from the
first implant removal (Rabbit #1) were available. After fixing and staining cross sections
of the implants, as described in the Materials and Methods Section of this report, the
slides were examined under a microscope.
Examination of sections of a coronal sectioned 400 micron dodecahedron block
revealed evidence of slight in-growth of cells, in addition a thin layer of fibroblast cells
was observed around the edges of the implant. Analysis of the cellular morphology
revealed that the cells within the implant were predominately necrotic.
Subsequently, sections from an 800 micron dodecahedron block were examined.
It is noted that sections from this block demonstrated tissue attachment in vivo as well as
apparent tissue in-growth and vascularization. Histologic examination of a coronal
section of a 800 micron dodecahedron block showed areas of both necrotic cells (Figure
26) and granulomatous tissue indicating an immune response (Figure 27). Also identified
were mast cell aggregates, neutrophils, syncytial cells, and large aggregates of
lymphocytes. These findings indicate an immune response, as well as the subsequent
occurrence of defense mechanisms. In addition, the appearance of red blood cells
surrounded by endothelial cells suggests the occurrence of neovascularization (Figure
28). The presence of necrotic cells as well as the apparent immune responses, in both the
400 and 800 micron dodecahedron blocks is most likely attributable to the cytotoxic
nature of the implant material.
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Implant material

Necrotic cells

Figure 26: Necrotic cells present in a coronal cross-section
of an 800 micron dodecahedron block.

Granulomatous tissue

Syncytial cell

Figure 27: Granulomatous tissue and syncytial cells
present in a cross-section of an 800 micron dodecahedron block (10x).
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Neovascularization

Figure 28: Neovascularization present in a cross-section of an 800 micron dodecahedron
block.

CONCLUSION
The objective of this study was to develop a porous polymeric implant, using 3D
printing technology, which facilitated soft tissue in-growth for use in subcutaneous and
percutaneous applications. Through the use of CAD software, and with the assistance of
the AMC at the University of Maine, Orono, 3D designs for both porous subcutaneous
and percutaneous implants were developed. With the assistance of the MAC at the
University of Southern Maine, Gorham, the 3D designs were printed and evaluated. After
several design iterations, implants were produced for in vivo analysis in a small animal
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trial. In addition, a cell culture experiment was performed to test basic cell adhesion and
material biocompatibility.
The porous matrix comprised a repeated pattern of interconnected rhombic
dodecahedra which are stacked on top of each other. The porous matrix was employed in
a rectangular block for subcutaneous implantation, and a button shape for percutaneous
implantation. The internal dodecahedral pore diameters of the implants tested in the small
animal trial were 400, 800, and 1200 micron (approx).
Cell culture data indicated that the plastic material (Vero White Plus Fullcure
835) employed to construct the implants was toxic to Buffalo Rat Liver cells and as such
resulted in little to no cellular attachment. The small animal trial demonstrated that the
400 micron subcutaneous blocks did not facilitate tissue attachment or tissue in-growth.
However, the 800 micron dodecahedron blocks, 1200 micron dodecahedron blocks, and
1200 micron dodecahedron buttons all achieved considerable tissue attachment and soft
tissue in-growth based on gross anatomical analysis.
Histologic examination of the in vivo implants indicated overwhelming necrosis
and immune response of the in-grown tissue, although neovascularization was observed.
The histological results are likely attributable to the cytotoxic nature of the implant
material used.
In conclusion, although the non-biocompatible nature of the implant material
resulted in necrosis of the in-grown tissue in vivo neovascularization and gross
anatomical analysis suggests that the implants were successful in meeting the objective of
facilitating soft tissue in-growth. Ongoing work is focused on repeating the study with
blocks and buttons made from a known biocompatible polymer. In addition, further work
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will be performed to refine both the pore and overall implant designs. Potential
applications for implant designs that did not demonstrate tissue in-growth (i.e. 400
micron block) will also be explored.
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APPENDIX C: Sterilization Test
STERILIZATION TEST
1. Place one 400 micron dodecahedron button, 400 micron dodecahedron block, and
800 micron dodecahedron block in individual 50mL conical tube. Add 7.5%
hydrogen peroxide (H2O2) to each of the three conical tubes until implants are
completely submerged.
2. Place 50mL conical tubes on rocker for 20min.
3. Remove 50mL conical tubes from rocker and decant H2O2 from each tube.
4. Add 70% ethanol (EtOH) to each of the three conical tubes until implants are
completely submerged.
5. Place 50mL conical tubes on rocker for 20min.
6. Remove 50mL conical tubes from rocker and decant EtOH from each tube.
7. Add sterile RPMI-1640 culture medium (Sigma-Aldrich) to each of the three
conical tubes until implants are completely submerged.
8. Place 50mL conical tubes on rocker for 5min.
9. Remove 50mL conical tubes from rocker and decant RPMI-1640 culture medium
from each tube into separate sterile 50mL conical tubes.
10. Aseptically streak ~20μL of RPMI-1640 culture medium decanted from each tube
in step 9 onto separate halves of P1100 blood agar plates (TSA w/5% sheep blood
– Northeast Laboratory Services).
11. Aseptically streak ~20μL of RPMI-1640 culture medium onto one half of P1100
blood agar plate (TSA w/5% sheep blood – Northeast Laboratory Services) as a
control.
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12. Incubate blood agar plates from steps 10 and 11 at 37oC for 48hr.
13. Remove plates and observe for bacterial growth.
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APPENDIX D: Cell Culture Experiment
CELL CULTURE EXPERIMENT
1. Thaw Buffalo Rat Liver (BRL 3A) cells (ATCC biological resource center) and
then propagate in Minimum Essential Medium Eagle (Sigma-Aldrich) in a 37oC
humidified incubator with 5% CO2 in air.
2. Allow cells to culture for several days until 80-90% confluent growth on bottom
of tissue culture flask is observed.
3. Upon observation of 80-90% confluent growth remove tissue culture flask from
incubator. Decant medium and rinse with 10mL of serum-free Minimum Essential
Medium.
4. Re-suspend cells by adding 7mL of 0.25% Trypsin-EDTA (Sigma-Aldrich) to
tissue culture flask.
5. After 10min pour cell suspension from tissue culture flask into 50mL centrifuge
tube. Add 10% fetal bovine serum in Minimum Essential Medium to centrifuge
tube to stop effects of trypsin and stabilize cells.
6. Centrifuge cell suspension at 1050 rpm for 7min using a slow deceleration.
7. Decant supernatant from centrifuge tube and re-suspend pellet by adding
Minimum Essential Medium and gently aspirating with pipette.
8. Analyze cell concentration of suspension resulting from step 7 using a
hemocytometer.
9. If needed, add additional Minimum Essential Medium to cell suspension to
increase total volume and obtain appropriate cell concentration for seeding
implants. Analyze cell concentration of diluted suspension using hemocytometer.
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10. Place sterilized implants, plastic material, or support material into individual wells
of sterile 8-well tissue culture plates.
11. Seed objects in step 10 with cell suspension in step 9 by adding 4-5mL of cell
suspension to each well. Add 4-5mL of cell suspension to empty wells as control.
12. Place tissue culture plates in 37oC humidified incubator with 5% CO2 in air for
24hr.
13. Remove tissue culture plates from incubator and use an inverted microscope to
examine individual wells and seeded objects for cell attachment.
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APPENDIX E: IACUC Protocol
IACUC PROTOCOL REVIEW FORM
PROTOCOL NUMBER:

August 2010 version

UNIVERSITY OF MAINE
PROTOCOL REVIEW FORM
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE

GENERAL INSTRUCTIONS: The Institutional Animal Care and Use Committee (IACUC)
consists of scientists from several disciplines as well as non-scientists, members of the University
community, and persons who have no other affiliation with the University than as members of the
Committee. The protocol should therefore be described in terms understandable by an audience
of educated nonspecialists. Please return the completed protocol to the Institutional Animal
Care and Use Committee, c/o Office of the Vice President for Research, 114 Alumni Hall.
The form is due TWO weeks prior to a scheduled IACUC meeting. The meeting dates are
posted at: http://www.umaine.edu/research/research-compliance/institutional-animal-care-and-usecommittee-iacuc/meeting-schedule-and-protocol-due-dates/. Protocols received late will be held
until the next month’s meeting. Please call Gayle Jones at 1-1498 if you have questions.
The Principal Investigator or Instructor must justify the ethical costs of using live animals by
demonstrating a reasonable expectation that such usage will contribute to the advancement of
knowledge which may eventually benefit humankind and/or animals. The Principal Investigator
or Instructor must further demonstrate that he or she has applied the concepts of "alternatives" in
designing the protocol. The term “alternatives” includes three components: replacement (using
organisms that are phylogenetically lower, cell cultures, tissues from slaughter or autopsy, or
nonanimal systems); reduction (in the number of animals used); and refinement (of design and
methods to reduce pain and stress to animals used as well as ensuring that the number of animals
used is optimal for the analysis proposed).
1.

Principal Investigator, Co-Investigator(s), or Instructor(s), with campus address, office
phone, and lab phone of PI (NOTE: The Principal Investigator or Instructor must be a
faculty member or professional staff):

Principle Investigator:
James A. Weber, DVM, PhD
Dept. of Animal and Veterinary Sciences, Univ. of Maine, 581-2774
Co-Investigators:
Ian D. Dickey, M.D., F.R.C.S.C.,
Medical Director, Orthopaedic Oncology, Adult Reconstruction
Eastern Maine Medical Center
Adjunct Professor
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Department of Chemical and Biological Engineering, Univ. of Maine
417 State Street – Suite 20
Bangor, Maine, U.S.A. 04401
(207) 973-8840
David Neivandt, Ph.D.
Associate Professor
Dept. of Chemical and Biological Engineering, University of Maine
581-2288
Anne Lichtenwalner, DVM, PhD
Dept. of Animal and Veterinary Sciences, Univ. of Maine, 581-2789
Title and number of course/Title of project:
In-Vivo Evaluation of Skin and Subcutaneous Tissue In-Growth into Porous Polypropylene
Implants Using a Rabbit Implant Model
Project/Course Start Date: January 1, 2012
Number of years project is planned to continue: three
(IACUC approval is granted for three years)
If this is a renewal application, please enter the exact project or course title and previous protocol
code. Be sure to identify any changes from the previously approved protocol.
n/a
Funding agency for project, if applicable. Include title of proposal if different from this
protocol.
Internal UMaine Funding sourced from the Institute for Molecular Biophysics, together
with a Carolyn E. Reed Pre-Medical Thesis Fellowship
2.

Describe the (check appropriate category) __X__research, ____teaching, or
____production objectives (not procedures) that involve use of animals. Explain these
objectives in non-technical language. Do not paste in sections of grant proposals.
The importance of soft tissue fixation in total joint, tumor, tendon and ligament
reconstruction is becoming increasingly apparent throughout the field of
orthopaedic surgery. The inability to successfully form a water tight seal between
skin and currently available transcutaneous orthopedic devices results in early
implant failure due to infection of deep tissues and bone. The inability of soft tissue
to form a strong attachment to solid metal implants is currently a significant cause
of limited postoperative function in orthopedic procedures such as external fixation
of fractured limbs. Work completed by this group and by others has demonstrated
that orthopedic implants composed of metal foams with pores of trabecular
architecture allow ingrowth of both bone and soft tissue to form a strong tissuedevice attachment. While early work has shown promise, two major issuse remain:
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First, can transcutaneous foam implants form a watertight seal with healing skin
that excludes bacteria from deeper tissues; and second, can non-metallic materials
currently used in orthopedic devices (high density polypropylene, for example) be
modified to stimulate tissue-implant adhesion through the introduction of small
pores into the material? To our knowledge, there is no such attempt to quantify
these factors for soft tissue, including skin and subcutaneous tissues.
This study tests the ingrowth of skin and subcutaneous tissue in rabbits to
"buttons" made of a novel polypropylene foam that is built on a three dimensional
printer. Our objectives are to compare ingrowth of skin and subcutaneous tissues
into plastic foam devices that are surgically implanted through the skin of rabbits.
We plan to quantitate the degree of in-growth of rabbit cells into the porous
matrices of these implants. Rabbits will be sacrificed and implants harvested at
three or six weeks post-implantation, and implants will be evaluated grossly for
tissue form, and histomorphologically for tissue-prosthetic ingrowth. The
comparision between groups will be to determine if the rates of ingrowth are
comparable or different, and within each group, what degree of ingrowth is evident
on histologic examination.
3.

Describe how this use of animals contributes to the advancement of knowledge, which
may eventually benefit humankind and/or animals.

Orthopaedic reconstructive surgery has improved the lives of many people since the
development of the hip replacement. Despite the success of today's orthopaedic implants,
significant morbidity, functional loss, and ultimate prosthetic failure is all-too-often
associated with these procedures. The inability to successfully reattach soft tissue (skin,
tendons and ligaments) directly to endoprosthetics is a significant limitation of current
orthopaedic implants. This study focuses on a new method for soft tissue attachment to a
novel non-metal endoprosthesis. This and future studies will offer new opportunities to
improve the success of external fixation of fractures and soft tissue reconstruction by
decreasing current orthopaedic postoperative infection rates in human patients.
4.

Identify the animals to be used (genus and species) and number (for the entire project).

Domestic rabbit (Oryctolagus cuniculus; New Zealand White strain, 4 to 4.5 kg each).
n = 6 animals)
5.

State the rationale for use of this/these species. Address the issue of replacement by
explaining why educational or research objectives cannot be met by the use of
phylogenetically lower organisms, cell or tissue cultures, or non-animal systems. (Please
note: the IACUC does not consider "hands-on experience" to be in and of itself an
adequate educational objective, unless the course serves students whose anticipated
educational and professional futures will require the skills imparted through such handson experience. If that is true in this instance, please describe the student population that
typically enrolls in the course.)

The objective of this study is to predict the interactions of various porous orthopedic
implants with surrounding tissues during the post-surgical recovery period in human
patients. A variety of systemic interactions occur during wound healing, and there are no in
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vitro options that accurately mimic the local conditions, cell types and immune system
interactions that occur in a live mammal.
6.

Justify the number of animals:
a.

Explain how the number of animals required fits your experimental design or
teaching or production/breeding objectives.

This is a pilot study where we plan to use small numbers of animals to
determine the growth of soft tissue into previously untested implant material. We plan to
initially test the biocompatibility of plastic orthopedic discs that are taped to the skin of
rabbits. If the material shows no reaction after seven days, we then plan to subcutaneously
implant solid implants of the plastic material into the same two rabbits (one implanted for
three weeks post-surgery, and the other for six weeks). If the initial study shows that the
material is biocompatible with subcutaneous tissues, and subcutaneous tissues grow into the
foam implants, then we will conduct a second study where we compare the growth of skin
and subcutaneous tissues into plastic foam implants within the same animal. This study will
use an additional four rabbits, two sacrificed at 3 weeks post-surgery and two sacrificed at
six weeks post-surgery. In this case, a disc-shaped plastic foam implant with a cylindrical
process will be implanted so that the implant contacts both subcutaneous tissues and skin,
and a portion of the cylindrical process extends above the surface of the skin so that it is in
direct contact with the edges of the skin incision.

b.

Give the rationale for the number in terms of the statistical methods to be used.
Address the issue of reduction by explaining why the proposed number is
sufficient, but not excessive. (A simple statement that the number proposed is
required for statistical significance is not an adequate response.) See How to do a
Power Analysis. For research in which the number of animals is limited not by
statistical power, but by the number of animals that can be captured, maintained,
or sampled, a power analysis will provide an indication of the statistical power of
the proposed tests based on the variance measured by the researcher, or others, in
previous studies. For studies not amenable to a Power Analysis (e.g., no data on
variability available, only descriptive data available), provide a justification for
why a power analysis is not appropriate for your project.

This is a pilot study where we plan to obtain results that may be used as preliminary data to
support additional outside funding for this line of research.

7.

PROCEDURES

The Committee does not wish to receive copies of research proposals or laboratory manuals. The
Principal Investigator or Instructor is asked to address succinctly the following questions,
as applicable. Special care should be taken to justify any procedures generally
discouraged by the University's code of ethics and policy.
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a.

Major categories of procedures. Please check the appropriate box for each
category.
Any “yes” responses must be described in sections b. (nonsurgical
procedures) and/or c. (surgical procedures) that follow. Please attach the
category headings (from 1-16 below) to the description of procedures in
sections 7b and c.

Yes

No
1.
2.
3.

collection or capture
kill and harvest tissue
immunization for antibody production: describe antigen, adjuvant used,
route of immunization, method of obtaining blood
4.
physiologic measurements
5.
dietary manipulations
6.
pharmacology/toxicology: material used, route of administration, etc.
7.
behavior studies
8.
environmental stress, e.g., temperature, restraint, forced exercise
9.
irradiation: type, facility to be used
10.
hazardous materials, e.g., carcinogens, radioactive materials
11.
biohazardous or infectious agents (use of Class 2 or higher agents
requires the approval of the University's Biosafety Committee)
12.
experimental trauma
13.
nonsurvival surgical procedure
14.
survival surgical procedure (animal is allowed to recover for any length
of time)
15.
multiple major operative procedures from which animal is allowed to
recover
16.
other, specify:
Skin surface testing of plastic implants for chronic inflammatory response
b.

Nonsurgical Procedures:
Describe all nonsurgical manipulations or procedures, if any, involving the
animal, e.g., drug administration, blood collection, diet change, collection,
capture. Specify the drug(s), dose, route of administration, or other methods
used. Specify duration of procedures. If an adjuvant will be used, state the
number of injection sites per dosage and the number of doses.

Rabbits will be transported to the Small Animal Research Facility at least one week prior to
surgery to allow a period of acclimatization. Animals will be examined for general health
and normal feeding / grooming behavior daily for the duration of the project. At twice
weekly intervals, rabbits will be subjected to a more thorough physical exam and will be
weighed.
Skin test - We plan to initially test the biocompatibility of plastic orthopedic discs that are
taped to the shaved skin of rabbits. The plastic discs will be affixed using medical grade
bandages to a site where the rabbits will not be able to remove them, and will remain for 7
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days. Following the skin test, the skin will be visually examined for signs of an
inflammatory reaction to the plastic.
Will the animals be killed? If so, what method of euthanasia will be used?
(Include dosages if applicable.) See the 2007 Report of the AVMA Panel on
Euthanasia for assistance
(http://www.avma.org/issues/animal_welfare/euthanasia.pdf). If not, what final
disposition of the animals is planned?
Rabbits will be humanely euthanized at the end of the post-surgery recovery period (either
three or six weeks) by an overdose of sodium pentobarbital (88 mg/kg of body weight) that
will be injected intravenously. All euthanasia will be performed by Dr. Weber, DVM, PhD.
If euthanasia becomes necessary, due to unplanned injury or illness to the
animal(s), how will it be accomplished (include dosages if applicable)? See the
2007 Report of the AVMA Panel on Euthanasia for assistance
(http://www.avma.org/issues/animal_welfare/euthanasia.pdf). NOTE: question must
be answered.
In the event of an unplanned injury or unanticipated post-surgical complication, rabbits
will be humanely euthanized by an overdose of sodium pentobarbital (88 mg/kg of body
weight) that will be injected intravenously. All euthanasia will be performed by Dr.
Weber, DVM, PhD.
c.

Surgical Procedures:
Describe briefly any surgical procedures. Describe the anaesthetic method,
including all drugs, dosages, routes of administration, and supplementation
schedules. Describe the postsurgical monitoring and care procedures, including
what response(s) you will look for to indicate recovery, and the method of
euthanasia (if it becomes necessary due to unplanned injury or illness).
The orthopedic implants will be composed of a biocompatible plastic
material. Internal structure of the implants will either be of a foam-type
with a trabecular inner structure and a defined pore size, or solid, with no
internal structure (control implants). The implants will be made from
Durus White Fullcure 430, a polypropylene-like material with desired
mechanical properties. The three-dimensional implants will be
manufactured by the Advanced Manufacturing Center (AMC) at the
University of Maine, using an Objet rapid prototyping machine.
After appropriate anesthesia (induction with xylazine (6 mg/kg i.m.), then
ketamine (25-30 mg/kg i.m.)), each rabbit will be maintained in a surgical
plane of anesthesia via inhalant isoflurane that is delivered through a closefitting surgical mask covering the mouth and nose. After rabbits are in a
surgical plane of anesthesia, a superficial posterior approach to the
subcutaneous layer overlying the spine will be performed through a single
incision through the skin directly on the dorsal midline from the mid thorax
to the lumbar region of the back. This skin incision will be approximately 12
to 15 cm in length. For the initial two surgeries, where a rectangular block
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of high density polypropylene foam is inserted subcutaneously, four pockets
(one on each side of midline) will be created between the skin and the dorsal
paraspinal muscles for insertion of the four plastic implant blocks. Two
blocks will have a trabecular foam structure (pore size of 527 micrometers
and a strut thickness of 122 micrometers), and two will be made of solid
plastic using the same material. Each block will be rectangular in shape,
with dimensions of 4 cm x 3 cm x 1 cm. The blocks will be spaced about 4
cm from each other between the subcutaneous tissue and the fascia. In each
pocket, the block will be secured by anchoring it with vicryl sutures at
opposite corners. After block placement, the wound will be irrigated and a
layered closure will be performed with subcuticular closure and a sterile
dressing. The dressing will be mildly compressive in nature.
Upon successful recovery and healing of the subcutaneous foam blocks
within the two initial rabbits, transcutaneous "buttons" made of high
density polypropylene-like foam will be implanted into the subcutaneous
tissues of four additional rabbits. The surgical anesthesia and approach will
be similar to the initial two surgeries, but four smaller incisions (one for
each implant) will be made into the skin overlying the dorsal paraspinal
muscles at the level of the thorax (two incisions just left of center and two
just right of center). A plastic implant with a larger (2 to 3 mm in diameter)
oval-shaped base attached to a smaller (0.7 cm in diameter and about 1 cm
tall) cylindrical projection will be affixed between the skin and the
underlying tissues so that the small cylindrical portion spans the transcutaneous junction and extends above the skin. The larger oval portion will
remain in the subcutaneous space to act as an anchor. After implant
placement, the wound will be irrigated and a layered closure will be
performed with subcuticular closure and a sterile dressing. The dressing will
be mildly compressive in nature.
Our main post-operative concerns will be the pain associated with the
healing of the skin wounds and the subcutaneous pockets, and the risk of
post-operative infection of the implant sites. To minimize these
complications, rabbits will receive standard intra-operative and postsurgical care. Surgeries will be performed by an orthopedic surgeon with
assistance by a veterinarian and veterinary technician in a veterinary
surgical suite. All personnel in the operating theater will be appropriately
gowned, and strict sterile technique and maintenance of sterile fields will be
followed. Rabbits will be kept warm throughout the procedure with a
pediatric surgical warming unit, and their vital signs will be monitored
regularly by the veterinary technician through physical signs and with an
electronic unit that monitors the rabbit's pulse rate and tissue oxygen
saturation. All animals will be given antibiotics (cefazolin at 25 mg/ kg i.m.
at one hour pre-op, and at 12 hour intervals post-op for at least 24 hours),
non-steroidal anti-inflammatory agents (5 mg/kg of carprofen s.c. at one
hour pre-op, and at 24 hour intervals post-surgery for one to two doses) and
a morphine agonist for analgesia (buprenorphine at 0.01 mg/kg immediately
post-wound closure, then at 12 hour intervals post-surgery until activity
patterns and feeding behavior have returned to normal levels). They will
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receive appropriate care from the staff of the Lab Animal Facility under the
supervision of Dr. Weber. Indications of pain or distress (i.e., cowering,
agitation, lack of defecation/ urination or lack of interest in food ) and postoperative complications (gross decrease in body weight, self mutilation,
overwhelming sepsis, wound abscesses or ulcers) will be addressed through
additional veterinary care (all workers in the lab animal facility will be
trained to recognize these signs of distree in the post-operative rabbits).
Rabbits that do not respond to treatment will be removed from the study
and humanely euthanized with an overdose of sodium pentobarbitol as listed
in Section 7a. At the end of the post-operative recovery period, rabbits will
be sacrificed as described in Section 7a. Following euthanasia, each plastic
implant and surrounding soft tissue will be harvested en bloc, taking care to
avoid disruption of the skin/ implant interface. The tissue will be prepared
for histological sectioning and microscopic examination to assess the degree
of tissue invasion of the spaces within the trabecular foam implants.
Is animal allowed to recover for any length of time? Yes/No Yes. If yes, how
long will animal survive surgery?
Three weeks post-surgery (n=3) or six weeks post-surgery (n=3).
If there is potential for discomfort or pain as a result of the procedures, describe
their nature and duration. Explain what will be done to relieve them, including
drugs and dosages, nursing care, mechanical devices, etc.
See response in section describing surgical and post-surgical procedures.
d.

Search for Alternatives: If the proposed procedures cause more than momentary or slight
pain or distress to the animal(s), federal regulations require that you search for
alternatives. The PI must provide a written narrative description (see NOTE below) of
the sources used to determine that less painful alternatives are not available. To fulfill
this requirement, bibliographical searches may be performed through the Animal Welfare
Information Center (AWIC) of the National Agriculture Library
(http://awic.nal.usda.gov/nal_display/index.php?info_center=3&tax_level=1&tax_subject=184 ).
Will the proposed procedures cause more than momentary or slight pain or distress to the
animal(s)?
No. (Examples of procedures for which this response is appropriate include
observation of behavior under conditions of little or no distress, dietary
manipulations, and injections or blood sampling by qualified personnel.)

Yes. (Examples of procedures for which this response is appropriate
include survival surgery, nonsurvival surgery, electrofishing, and
procedures producing pain or distress unrelieved by analgesics such as
toxicity studies, microbial virulence testing, radiation sickness, and
research on stress, shock, or pain.) The required narrative is attached.
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NOTE: When preparing the narrative, the instructions in the USDA
policy MUST be followed. For a description of this policy, see:
http://www.aphis.usda.gov/animal_welfare/downloads/policy/policy12.pdf.
Animal Welfare Information Search
Databases searched were Medline and the AWIC site. Both sites were searched on November 1,
2011.
Medline Search ID # S1 ((orthopedic surgery) or (porous plastic foam) or (trabecular plastic) or
(soft tissue reconstruction) or (endoprosthesis)) and non-surgical. Limiters - Date of Publication:
1995/01-2011/11; Abstract Available; Languages: English; Animals: Rabbits
Expanders - Automatically "And" search terms Interface - EBSCOhost
Search Screen - Advanced
Database - MEDLINE 59 hits
The Medline search did not reveal non-surgical alternatives that would adequately address the
interactions of mammalian tissues with the type of implants used in the proposed study.
Furthermore, the only study design that is Federally approved for pre-clinical studies of human
prosthetics is a mammalian whole animal model, and the ultimate goal of the proposed work is
the development of an orthopedic device that could be used in human medicine.
AWIC Website. After examining the resources on the website, we found that the most useful link
for our discipline was the AltWeb site. AltWeb Search: We examined articles in this database,
but did not find alternatives to surgery for the proposed study. We did find useful information on
side effects of specific anesthetic combinations in rabbits, and guidelines for the recognition and
assessment of animal pain. This information was incorporated into the IACUC proposal.

NOTE: When proposed procedures will cause more than
momentary or slight pain or distress to animal(s), a consultation
with the attending veterinarian must occur in the planning
stages of those procedures prior to submitting this protocol for
review. Please email Dr. James Weber, james.weber@umit.maine.edu,
with a description of the proposed procedures and your approach to
minimizing pain/distress.
8.

Animal Sources and Housing

a.

Please indicate source of animals. Note: The IACUC will approve animal purchases
from a licensed pet store provided the researcher/instructor informs the pet store
(in writing) that the purchased animals will be used for research/teaching.
New Zealand White rabbits will be obtained from Charles River
Laboratories.
b.

If the animals are caught in the wild: n/a
Where and how will the animals be trapped?
How often will the traps be checked?
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What other steps will be taken to protect the animals from exposure or other danger?
Indicate if Federal/State permits are required and whether they have been obtained.
If the animals will be brought to the campus, what precautions will be taken to prevent
zoonotic diseases?
Please include your plans for removal of traps or barriers (e.g., pitfall traps).
c.

Where will the animals be housed? Describe the housing (See the Guide for the
Care and Use of Lab Animals (http://www.nap.edu/readingroom/books/labrats/)
pages 22-36) for information on Physical Environment, including space
requirements. If your housing will not meet the Guide requirements, include a
request for an exception to the Guide. If your animals are not listed in the Guide,
housing should meet the recommendations of the appropriate guidelines for the
proposed species. Include dimensions of cage, tank, etc.

Rabbits will be housed one animal per cage in standard laboratory rabbit
cages (stainless steel bars, with slotted plastic floor, dimensions = 18 inches high by 26
inches wide by 26 inches deep. These cage dimensions will allow rabbits in the 4.0 kg weight
range to stand up in and move freely about the cage) within one of the animal rooms in the
Small Animal Research Facility on campus. Rabbits will be housed individually, but will
have visual and auditory contact with other rabbits in the same room. Rabbits will be given
enrichment items (i.e., rabbit-safe gnaw toys), and will receive daily human contact from
the animal caretakers.
d.

Identify the room or facility in which the procedures will be conducted.

Housing - one of the five lab animal rooms in the Small Animal Research Facility.
Surgeries - performed in the surgery suite within the Small Animal Research Facility includes dedicated pre-operative, operative and post-operative areas, and HEPA filtered
ventilation within the surgery room.

9.

List all person(s) (including PI) who will handle animals (e.g., carry out the procedure(s),
animal care, etc.) or provide training of personnel. For each person named below,
describe his/her experience in performing proposed procedures; if none, explain how
training will be obtained.

Name/Title/Experience
James Weber, DVM, PhD. Dr. Weber is a licensed veterinarian (DVM in 1994) with training
and over twenty years of experience in the anesthesia and surgery of laboratory animals,
including rabbits, rats, mice and laboratory swine. He and Dr. Dickey successfully completed
an orthopedic surgery-based study of 36 rabbits at UMaine in 2007.
Ian Dickey, MD, FRCSC. Dr. Dickey is a licensed orthopedic surgeon who is currently
practices in the orthopedic reconstruction center at Eastern Maine Medical Center. He is also a
cooperating research professor in the Department of Biological and Chemical Engineering. Dr.
Dickey has been the primary investigator for numerous orthopedic research studies in the area
of tissue ingrowth into foam metal implants, and he routinely performs orthopedic and

66
reconstructive surgeries on human patients in his current practice at EMMC.
Dr. Anne Lichtenwalner is a veterinary scientist who currently does animal-related research
and oversees Maine's Animal Health Laboratory. She has over twenty years of experience with
lab animal medicine, and acted as the Institutional Veterinarian for the University of
Washington. Anne also has extensive experience with a variety of surgical and non-surgical
procedures on both large and small animals.
Brenda Kennedy-Wade. Brenda is a veterinary technician who is currently licensed in the
State of Maine. She has been the professional staff member in charge of animal care at the
Small Animal Research Facility for over ten years. She has also assisted investigators in
virtually all of the surgery and post-operative care that has been conducted at the SARF during
that time.
Alex Caddell. Alex is a senior biological engineering student at the University of Maine and will
be involved with the research as part of his Honors Thesis project. Training will be obtained
from Dr. Weber and Dr. Dickey. Alex will observe the surgeries, but will not be part of the
surgery team. He will be a member of the post-operative animal monitoring team.
10.

If animals will be housed, please list the name, phone number, and email of the person
who should be contacted to accompany the IACUC during facility inspections:

Brenda Kennedy-Wade, 581-2775; brendakw@maine.edu
11.

Have all personnel named above been certified by the IACUC for Responsible Care and Use
of Animals?
Yes
No A web-based tutorial for this certification is available at:
http://umaine.edu/research/research-compliance/institutional-animal-care-and-use-committeeiacuc/web-based-training/. (Note: protocols will not be processed until all personnel have been

certified.
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12.

Risk Assessment (risks to researchers):
In compliance with our Public Health Service Animal Welfare Assurance, we have
implemented an Occupational Health/Medical Surveillance Program. The first step will
be for investigators to identify potential hazards with tasks involved with the study, so the
IACUC veterinarian and Safety and Environmental Management (SEM) can assess the
risks to determine if further information will be required from everyone named in the
protocol (i.e., a health questionnaire).
Please complete the following for your proposed protocol.
a)

Provide a brief description of the protocol (cut and paste response from question
2 of the protocol). (NOTE: Only this page, not the whole protocol, goes to SEM
and the Occupational Health Physician, thus the request for duplication of the
answer to question 2.)
The importance of soft tissue fixation in total joint, tumor, tendon and ligament
reconstruction is becoming increasingly apparent throughout the field of
orthopaedic surgery. The inability to successfully form a water tight seal between
skin and currently available transcutaneous orthopedic devices results in early
implant failure due to infection of deep tissues and bone. The inability of soft tissue
to form a strong attachment to solid metal implants is currently a significant cause
of limited postoperative function in orthopedic procedures such as external fixation
of fractured limbs. Work completed by this group and by others has demonstrated
that orthopedic implants composed of metal foams with pores of trabecular
architecture allow ingrowth of both bone and soft tissue to form a strong tissuedevice attachment. While early work has shown promise, two major issuse remain:
First, can transcutaneous foam implants form a watertight seal with healing skin
that excludes bacteria from deeper tissues; and second, can non-metallic materials
currently used in orthopedic devices (high density polypropylene, for example) be
modified to stimulate tissue-implant adhesion through the introduction of small
pores into the material? To our knowledge, there is no such attempt to quantify
these factors for soft tissue, including skin and subcutaneous tissues.
This study tests the ingrowth of skin and subcutaneous tissue in rabbits to
"buttons" made of a novel polypropylene foam that is built on a three dimensional
printer. Our objectives are to compare ingrowth of skin and subcutaneous tissues
into plastic foam devices that are surgically implanted through the skin of rabbits.
We plan to quantitate the degree of in-growth of rabbit cells into the porous
matrices of these implants. Rabbits will be sacrificed and implants harvested at
three or six weeks post-implantation, and implants will be evaluated grossly for
tissue form, and histomorphologically for tissue-prosthetic ingrowth. The
comparision between groups will be to determine if the rates of ingrowth are
comparable or different, and within each group, what degree of ingrowth is evident
on histologic examination.

b)

List the tasks required.
1. Care and feeding of rabbits.
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2. Surgical prep, general anesthesia surgery, surgical post-op, euthanasia using
pentobarbital overdose.
3. Administration of i.v. and i.m. injections, physical examination, bandaging of
post-operative wounds.
c)

For each of the tasks described in b) above, list the associated hazards.
1. Animal bites and scratches, risk of being kicked by rabbit hind limb.
2. Possible exposure to anesthetic drugs, risk of needle stick.
3. Needle stick, risk of being bitten or scratched , development of allergies.

d)

For each of the hazards described in c) above list how the hazards will be
managed.
1. All animal workers will receive hands-on training on the safe methods for
handling rabbits prior to their work in the animal room. Animal care workers
will wear nitrile gloves, eye protection and disposable coveralls during routine
care and feeding of rabbits. We do not anticipate that these animals will be
overly aggressive, based on their performance in many research studies. Heavy
canvas gloves will be worn when animals are handled.
2. All drugs will be handled and administered by trained personnel (Weber,
Kennedy-Wade), and University of Maine-approved procedures for handling
needles, scalpels and other sharps will be followed. Gas anesthetics are
scavenged out of the surgery room using an active ventilation system.
3. Protective equipment will be worn (as described in “1.”, and trained personnel
will perform all hands-on procedures with the rabbits (as described in “2.”.
Animal room and surgery suite are actively ventilated, which minimizes
exposure to potential allergens. Workers cleaning up bedding and animal wastes
will wear a particulate filtration mask to minimize inhalation of particulates.

NOTE: In evaluating this risk assessment statement, we will be looking for animal care tasks that
increase the risk of illness (such as a zoonotic disease), physical injury (such as animal bites),
and/or allergic reactions to those handling the animals.
After this risk assessment is reviewed, everyone named in the protocol may be required to
complete a health questionnaire. The health questionnaire may require review by the
Occupational Health Physician. If so, there is a charge for this review, and you will be
required to provide an account number. (Currently the charge is $45; we do not know the
cost of a physical exam if warranted after review of the questionnaire, but this page will be
updated when that information is known.)
If you have any questions regarding the completion of this page, please contact James
Patrick, Safety and Environmental Management, 1-4055.
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ASSURANCES FOR THE HUMANE CARE AND USE OF ANIMALS
As the Principal Investigator on this protocol, I assure that…
1)

I have provided an accurate description of the animal care and use protocol to be
followed in the proposed project/course.

2)

the activities proposed do not unnecessarily duplicate previous experiments.

3)

all individuals named in this application who are at risk will be registered in the
Occupational Health and Safety Program.

4)

all individuals performing animal procedures described in this application are technically
competent and have been (or will be) properly trained in the procedures to ensure that no
unnecessary pain or distress will be caused as a result of the procedures.

5)

I will obtain approval from the IACUC before initiating any changes to this protocol.

6)

I am familiar with and will comply with the University of Maine’s Policies and
Procedures for the Humane Care and Use of Animals, and I assume responsibility for
compliance by all personnel involved with this protocol.

7)

I have read and will follow the appropriate guidelines for the proposed species.

8)

if using laboratory animals, all personnel handling the animals have had a tetanus shot
within the past ten years.

9)

all applicable rules and regulations regarding radiation protection, biosafety, recombinant
issues, hazardous chemicals, etc., have been addressed in the preparation of this
application and the appropriate reviews have been initiated.

10)

animals will be purchased only from licensed, reputable vendors. If animals are
purchased form a pet store, the pet store has been informed (in writing) that the animals
will be used for research or teaching purposes.

11)

I will maintain appropriate animal records (e.g., census, health, veterinary care,
euthanasia, surgery, diagnostic, anesthesia, etc.)

12)

I will report at once to the IACUC any unanticipated harm to animals.

___________________________________________
Signature of Principal Investigator/Instructor

_____________________
Date

I hereby confirm that I have read this protocol and my signature denotes departmental
approval of this project.
___________________________________________
Signature of Department Head/School Director

______________________
Date
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Purpose:
The preservation of tissue samples. This SOP covers embedding tissue in paraffin block,
sectioning tissue block and placement of section on glass slide.
Hazards:
Wear a long-sleeved lab coat, goggles and nitrile gloves.
Formalin may cause severe irritation to skin, eyes and respiratory tract. While working
with 10% BF it is mandatory to work under a fume hood or in a hood equipped with
proper filter.
Specimen:
Fixed tissue.
Material Required:
Sample jar containing 1:15 sample to fixative volume.
Carbon steel blades – No.60 - No.8 handles
Tissue-tek™ tissue cassettes
No.2 pencil
Hyper-Clean™ hood with formaldehyde clearing filter.
Tissue processor
Tissue embedding center
Cold plate at - 4˚c
Leica RM2155 Microtome
Accu-Edge® Low Profile Blades.
FisherBrand® Superfrost slides- 25mm x75mm x1mm
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Water bath at 43˚-45c
Warming plate at 40˚c
10 % buffered formalin [BF]

Procedure:
Fixation:
1. Appropriately label specimen jar containing fixative.
2. Place selected tissue into jar – if amount of tissue exceeds the 1:10 volume
ratio, place excess tissue into additional specimen jar or add more fixative.
3. Let tissue sit overnight [20-24hrs.] at room temperature.
Trimming:
1. Trim tissue in Hyper-clean™ hood equipped with filter.
2. Pour tissue into metal strainer over measuring cup, once drained deposit
tissue onto trim board and pour fixative back into original specimen jar.
3. Closely follow pathologist’s directions when trimming tissue, ie. near
lesions and or special orientation of tissue, etc.
4. Tissue must be less than 4mm in thickness. Do not crowd tissue. If
possible, orient tissue exactly as it will be embedded in the paraffin block.
Place side of tissue to cut face down in the cassette.
5. Be sure to snap cassette lid tightly before placing into holding jar with
10% BF.
6. All samples remain in holding jar until the processing run begins.
Processing:
1. Check the tissue processor to confirm each station contains the proper
level of reagent. See S.O.P.: Operation of The Leica TP1020 Tissue
Processor.
2. Samples are processed in the Leica TP1020 overnight. The scheduled run
lasts approximately 16.5 hrs. - samples are placed in the processor around
4:00pm and removed the next morning around 8:30am. The processor
will beep to signify the end of the run.
3. Transfer the samples from the Leica TP1020 to the paraffin bath in the
embedding center.
Embedding:
1. Remove each cassette, one at a time, from the paraffin bath and place it
on the hot surface of the embedding center. Keep the cassette in contact
with the hot surface or the paraffin will start to solidify.
2. Select the proper sized metal mold and fill with paraffin.
3. Open the tissue cassette and begin transferring the tissue to the mold using
the warmed forceps sitting in the embedding center. The orientation of the
tissue is very important.

73
4. Do not place the blunt end of the tissue piece toward the primary cutting
edge of the block. If the knife hits the blunt end first it can create
shattering artifacts.
5. Once tissue is properly placed, slowly move mold to the cold area of the
center and gently touch tissue to lock in place.Transfer cassettes to the
cold plate to solidify the paraffin. The cold plate is kept at - 4˚c .
6. After the paraffin hardens remove the block from the mold and trim away
the excess paraffin.
7. The sample is ready for sectioning.
Sectioning:
1. Secure the tissue block in the microtome clamp and ALWAYS be
consistent with the orientation of the block in the clamp. If re-cuts are
necessary, the loss of sample is greatly reduced if the same orientation is
kept. For reference, the cassette label is always facing the right when in
the clamp.
2. Insert microtome blade in the blade holder. An older blade can be used for
rough cutting, but always use a new blade for fine sectioning. Use AccuEdge® Low Profile Blades. Gently wipe the edge of the blade with
solvent prior to placing in the blade holder.
3. The block must be rough cut to expose the entire face of all tissue in the
block.
4. Set the microtome at 15 or 30 microns to rough cut the block.
5. After rough cutting, place the tissue onto an ice block. The tissue block
must be cooled and moistened so that a suitable ribbon of tissue will
advance from the block when sectioning.
6. After approximately 30-45 min on ice, place block in the clamp and try
cutting.
7. Remember to place the new blade in the blade holder.
See SOP: Operation of the Leica RM2155 Microtome.
8. When a nice, flat ribbon of tissue advances from the block, carefully lift
the ribbon and float it onto the hot water bath [~ 44˚c], gently stretching
the tissue to eliminate wrinkling. Select the best section from the ribbon
and lift it off the water with the glass slide, lean slide upright against the
water bath to dry.
9. When dry, put slide onto slide warmer [~ 40˚c] to better adhere tissue
section to the slide’s surface. Slides can remain on warmer overnight. The
section is ready for staining.
Procedural Notes
Please read referenced S.O.P.’s prior to following this protocol.
Proper instruction in the operation of the tissue processor and the microtome must
be given
by lab personnel before processing any samples.
A copy of the lab submission form must accompany the sample to the histology
lab.
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References:
Laboratory Methods in Histotechnology, Armed Forces Institute of Pathology,
1992
Leica RM 2155 microtome guide book.
Leica TP1020 Tissue Processor guide book.
Revision History:
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Purpose
Operation of the Leica TP1020 tissue processor.
Hazards
1. Xylene is a moderate skin and eye irritant; toxic by ingestion, inhalation and skin
contact.
Repeated exposure produces neurotoxic effects, impaired memory, mood swings
and nerve
damage.Wear viton or Teflon gloves when dispensing.
2. Ethanol is a moderate to severe skin irritant and moderate eye irritant; ix toxic by
ingestion producing behavioral and gastrointestinal symptoms. Wear nitrile
gloves when dispensing.
3. Formaldehyde is a severe eye and skin irritant; toxic by ingestion and inhalation
and is considered carcinogenic. Wear nitrile when dispensing.
Specimen
Fixed tissue samples.
Material Required
1. 10% buffered formalin.
2. Deinoized water
3. Ethanol, 70%, 95% and 100%
4. Xylene – Histological Grade
5. Paraffin- Tissue Prep II
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6. Fixed tissue samples
7. Absorbent paper towels
Procedure:
Filling stations with reagents:
1. Remove each container from the processor and fill with the proper
reagent to just below the maximum fill line.
Station #1- 10% buffered formalin
Station #2- Deionized water
Station #3- 70% Ethanol
Station #4- 95% Ethanol
Station #5- 95% Ethanol
Station #6- 100% Ethanol
Station #7- 100% Ethanol
Station #8- 50:50 Xylene:100% Ethanol
Station #9- Xylene
Station#10- Xylene
Station#11- Paraffin
Station#12- Paraffin
Standard tissue processing schedule: 16.5hrs
1. Station #1- 4 hrs.
2.
#2- 1.5 hrs.
3. Stations #3 thru #10- 1hr. each.
4. Stations #11 and #12 –1.5 hrs.each.
Starting a run:
1.
2.
3.
4.
5.
6.
7.
8.

Open the plexi-glass enclosure.
Press ↑ to elevate the reagent covers.
Add tissue cassettes to the metal basket.
Slide basket into the holder at Station #1.
Press ↓ to lower the basket.
Run #1 is the standard tissue processing run ~16.5hrs.
Press Start/Prog/Start/Prog.
Close the plexi-glass enclosure.

To Stop or Abort a run:
1. Press Stop button.
2. Press Start button to resume the run.

End of a processing run:
1. The display will read “Done” - a beep will sound every 30secs.
2. Open the plexi-glass enclosure.
3. Press Stop to end the run.
4. Press ↑ to elevate the basket.
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5. To prevent paraffin from dripping on the floor, hold the basket in
paper towels while transferring samples from the processor to the
embedding station.
6. Quickly wipe the excess paraffin from the basket before it hardens.
7. Press ↓ to lower the reagent covers on the processor.
8. Close the plexi-glass enclosure.
Procedural Notes:
Refer to the Leica TP1020 Instruction Manual for more details.
Refer to the Programming Section of the above manual to program runs.
Reference Procedures:
Hazardous Materials in The Histopathology Laboratory, Regulations, Risks, Handling
and Disposal, 3rd Edition.
Leica TP1020 Tissue Processor Instruction Manual, 12/97
Revision History:
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Purpose
To automatically stain tissue sections with the standard hematoxylin and eosin [H&E]
stain.
Hazards
4. Xylene is a moderate skin and eye irritant; toxic by ingestion, inhalation and skin
contact.
Repeated exposure produces neurotoxic effects, impaired memory, mood swings
and nerve
damage. Wear viton or teflon gloves, a long-sleeved lab coat and goggles
when dispensing.
5. Ethanol is a moderate to severe skin irritant and moderate eye irritant; toxic by
ingestion producing behavioral and gastrointestinal symptoms. Wear nitrile
gloves, a long-sleeved lab coat and goggles when dispensing.
6. Hematoxylin [basic dye] is an equivocal tumorigenic agent in rats after ingestion
of large quantities. Wear nitrile gloves, a long-sleeved lab coat and goggles when
dispensing.
7. Eosin Y [acid dye] has been determined to be an equivocal tumorigenic agent.
Wear nitrile gloves, a long-sleeved lab coat and goggles when dispensing.
8. Acid alcohol reagent is 1% concentrated hydrochloric acid in 70% ethanol. –
wear nitrile gloves, a long-sleeved lab coat and goggles when dispensing.
Specimen
Tissue specimen mounted on a glass slide.
Material Required
1. Xylene
2. Ethanol 70%, 95% and 100%
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3.
4.
5.
6.
7.

Hematoxylin stain [Instant]- Thermo-Shandon
Eosin Y stain [Instant] – Thermo-Shandon
1% Acid alcohol
Ammonium water
Deionized water

Procedure
1. Fill stations with the following reagents:
a) Step #1 Station #1- Xylene
Time: 1.00min
b) Step #2
#2- Xylene
1.00
c) Step #3
#3- 100% Ethanol
1.00
d) Step #4
#4- 95% Ethanol
1.00
e) Step #5
#5- 70% Ethanol
1.00
f) Step #6
Wash #1
1.00
g) Step #7
#6- Hematoxylin
10.00
h) Step #8
Wash #2
1.00
i) Step #9
#7- Acid Alcohol
.05sec
j) Step #10
Wash #3
1.00
k) Step #11
#8- Ammonia water
2.00
l) Step #12
Wash #4
1.00
m) Step #13
#9- Deionized water
1.00
n) Step #14
#10- 95% Ethanol
1.00
o) Step #15
#11- Eosin
5.00
p) Step #16
#12- 95% Ethanol
.30sec
q) Step #17
#13- 95% Ethanol
1.00
r) Step #18
#14- 100% Ethanol
1.00
s) Step #19
#15- 100% Ethanol
1.00
t) Step #20
#16- Xylene
1.00
u) Step #21
#17- Xylene
2.00
2. Place slides into rack and place rack into LOAD drawer.
3. Select STAIN #1 from the Main Menu
4. Press LOAD button – light will go off and run will begin.
5. Close cover.
6. When the staining run is done, a beep will sound.
7. Press EXIT button- slide open drawer, remove rack.
8. Transfer the slide rack to xylene in table top hood.
9. Replace reagent covers on stain troughs and close stainer cover.
Procedural Notes
Refer to Leica XY Autostainer Guide,
Keep all solutions at the 400ml level – mid-pt. mark on the trough.
Change stains based on staining ability of the hematoxylin and eosin – check tissue under
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400x.
Change all remaining solutions based on use – approximately every #500 slides.
Reference Procedures
Refer to Leica XY Autostainer Manual.
Revision History
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APPENDIX I: 1200 Micron Pore and Button Dimensions

Figure 29: Measurement of 1200 micron pore

Figure 30: External dimensions of 1200 micron pore.
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Figure 31: External dimensions of 1200 micron pore.

Figure 32: Dimensions of 1200 micron button core and cap.
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Figure 33: Dimensions of 1200 micron button cage.

Figure 34: Dimensions of 1200 micron button cage.
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Figure 35: Dimensions of 1200 micron button porous matrix.

Figure 36: Dimensions of 1200 micron button porous matrix.

85
AUTHOR’S BIOGRAPHY
Alexander Graham Caddell was born in Middletown Springs, Vermont in 1990 and
moved to Winterport, Maine in 2000. He graduated from Hampden Academy in 2008 as
the class salutatorian. Alex attended the University of Maine as a biological engineering
major, having received the Top Scholar Award. He graduated from the University of
Maine in May 2012.

